CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Assess the anticipated benefits, risks and long-term outcomes associated with the use of adjuvant and neoadjuvant therapy in the management of Stage IB-IIIA non-small cell lung cancer (NSCLC), and consider this information when counseling individuals regarding current therapeutic recommendations.
  • Analyze the available efficacy and safety data on the use of immune checkpoint inhibitors as adjuvant and neoadjuvant treatment in patients with non-metastatic NSCLC, and consider the potential effect of this information on current and future clinical practice.
  • Recognize the roles of surgery and radiation therapy for the multimodal management of localized NSCLC within the context of evolving adjuvant and neoadjuvant paradigms in this disease.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized NSCLC, and counsel appropriate patients about availability and participation.
  • Evaluate the clinical relevance of the various genomic abnormalities found in patients with localized NSCLC, and appreciate ongoing research studies attempting to validate the efficacy of targeted therapy in these individuals.
  • Appreciate Phase III findings supporting the use of adjuvant osimertinib for patients with EGFR mutation-positive NSCLC after complete resection, and appropriately integrate this strategy in the adjuvant setting for eligible individuals.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jamie E Chaft, MD
  Associate Attending Physician
  Thoracic Oncology Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Flame Biosciences, Genentech, a member of the Roche Group, Guardant Health, Janssen Biotech Inc, Merck, Novartis, Regeneron Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck.
  
  Professor Solange Peters, MD, PhD
  Head, Medical Oncology
  Chair, Thoracic Malignancies
  Oncology Department
  Lausanne University Hospital (CHUV)
  Lausanne, Switzerland
  
  Advisory Committee and Consulting Agreements (All fees to institution): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm, Elsevier, Foundation Medicine, Genentech, a member of the Roche Group, Illumina, Incyte Corporation, IQVIA, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, PharmaMar, Phosplatin Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Lilly; Speaking Engagements (All fees to institution): AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Merck Sharp & Dohme Corp, Pfizer Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc.
  
  Brendon M Stiles, MD
  Professor and Chief
  Thoracic Surgery and Surgical Oncology
  Albert Einstein College of Medicine and Montefiore Medical Center
  Bronx, New York
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Flame Biosciences, Gala Therapeutics,Galvanize Therapeutics Inc, Genentech, a member of the Roche Group, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Galvanize Therapeutics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Galvanize Therapeutics Inc; Employment (Spouse): Xalud Therapeutics; Ownership Interest (Spouse): Pfizer Inc, PPD, Xalud Therapeutics; Other (Board Chair): Lung Cancer Research Foundation (accepts donations from pharma).
  
  Eric Vallieres, MD
  Surgical Director, Lung Cancer Program
  Swedish Cancer Institute
  Seattle, Washington
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Olympus; Data and Safety Monitoring Board/Committee: Razor Genomics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Oncocyte.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Genentech, a member of the Roche Group.
  
  Release date: November 2021
  Expiration date: November 2022